Daiichi Sankyo announces TaNeDS Global 2018 collaborative drug discovery program

Daiichi SankyoDaiichi Sankyo Company, Limited today announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global 2018, a collaborative drug discovery initiative for universities and research institutes in Europe and the East Coast of the United States.

The TaNeDS program was launched in Japan in 2011 to help discover new lines of research through open innovation. From 2013, it expanded outside of Japan, opening up to researchers in Europe. This year, based on past experiences and results, the program will be further expanded to include the East Coast of the United States and be known as “TaNeDS Global 2018”. The aim of the program, however, will continue to be increasing collaborative opportunities between Daiichi Sankyo and researchers outside of Japan.

About TaNeDS Global 2018 Collaborative Drug Discovery Program

1. Eligible Countries & US States
  • All EU member states plus Iceland, Norway, Switzerland and Israel
  • The East Coast of the United States: Connecticut, Delaware, the District of Columbia, Florida, Georgia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, North Carolina, Pennsylvania, Rhode Island, South Carolina, Vermont, and Virginia

2. Candidate Research for Application
New drug-target discovery, drug-target validation, and innovative technological research that could result in novel drug discovery and development

3. Research Themes
(1) Oncology
Novel targets and mechanisms for small-molecule and biologic treatments (antibody drugs, etc.)

(2) Pain and Sensory neural systems
Novel targets and compounds for pain and sensory neuronal systems in vision/hearing loss

(3) Cardiovascular and renal diseases
Novel targets and mechanisms for heart, kidney, and vascular diseases

(4) Other Diseases
Novel targets and therapeutics for genetic rare diseases, gut microbiome-related diseases, stroke and anemia

(5) Cell Therapy
Research on novel mesenchymal stem cell, novel somatic stem/progenitor cells, and adoptive T-cell therapy

(6) Technology and related research
Novel technology on nucleic acid therapeutics, gene therapy and biomarker research

Novel targets for nucleic acid therapeutics and protein therapeutics

For more details, please visit TaNeDS Global webpage at: http://www.daiichisankyo.com/rd/taneds/index.html

4. Budget and Period of Research
Depending on the project type, up to maximum of EUR/USD 75,000 (Type A) or EUR/USD 150,000 (Type B) (plus overhead) per year for collaborative research projects for 2 years

5. Eligibility
Researchers of any nationality employed by universities, research institutes and start-up companies within the EU, Iceland, Norway, Switzerland, Israel, and the East Coast of the United States who can conduct research in those countries

6. Selection criteria
By matching Daiichi Sankyo's research interests as well as demonstrating originality, potentiality and possibility of drug discovery

7. Schedule
Application period: January 10 to February 19, 2018

First shortlist selection period: Late February to Mid-March, 2018

Second shortlist selection period: April, 2018

On-site visit interview: Mid-May, 2018

Notification of final decisions: Mid-June, 2018

Start of research program: August 2018 and onward

About Selection Results for TaNeDS Europe 2017 Collaborative Drug Discovery Program
The selection for 2017 resulted in four projects, and the three collaboration are currently underway having one under negotiation.

(1) Applications: 56

(2) Selected: 4

The themes of four selected proposals are Pain (Denmark), Rare Disease (Spain), Microbiome (Germany), and Technology (Finland).

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

In mice, stem cells seem to work in fighting obesi…

Obesity is an increasing global health problem associated with several comorbidities and a high risk of mortality. A wide spectrum of interventions has been proposed for ...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Research shows how a moderate dose of alcohol prot…

For at least 20 years, research has shown that for many people, moderate consumption of alcohol can protect the heart, but the reason for this is poorly understood. A stu...

'Kiss of death' cancer

It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negativ...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...